Gordon W. Dewald focuses on Internal medicine, Immunology, Cytogenetics, Pathology and Leukemia. His research in Internal medicine intersects with topics in Gastroenterology, Surgery and Oncology. His work in Immunology addresses subjects such as Cancer research, which are connected to disciplines such as ABL, Gene rearrangement and Polycythemia vera.
Gordon W. Dewald has researched Cytogenetics in several fields, including Karyotype and Chromosomal translocation. Gordon W. Dewald combines subjects such as Stem cell marker, Trisomy, Immunophenotyping, Lymphocyte and Histamine with his study of Pathology. Gordon W. Dewald works mostly in the field of Leukemia, limiting it down to topics relating to Multivariate analysis and, in certain cases, Myelogenous and Cancer, as a part of the same area of interest.
The scientist’s investigation covers issues in Internal medicine, Pathology, Cytogenetics, Immunology and Chromosome. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Surgery and Oncology. His Pathology study combines topics from a wide range of disciplines, such as Fluorescence in situ hybridization and Chromosome abnormality.
His Cytogenetics research is multidisciplinary, incorporating elements of Clone, Monosomy, Karyotype and Chromosomal translocation. His research investigates the connection between Immunology and topics such as Cancer research that intersect with problems in ABL. Gordon W. Dewald has researched Myelodysplastic syndromes in several fields, including Hematology and Myeloproliferative Disorders.
His scientific interests lie mostly in Internal medicine, Oncology, Pathology, Immunology and Surgery. His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology. His Oncology research integrates issues from T cell and False Negative Reactions.
His work deals with themes such as Cancer, Karyotype, Monoclonal gammopathy, Cytogenetics and Fluorescence in situ hybridization, which intersect with Pathology. His Immunology research is multidisciplinary, relying on both Molecular biology and Disease. In his study, Myeloproliferative Disorders, Neutropenia, Lenalidomide and Cancer research is strongly linked to Myelodysplastic syndromes, which falls under the umbrella field of Hematology.
Internal medicine, Surgery, Pathology, Chronic lymphocytic leukemia and Transplantation are his primary areas of study. Gordon W. Dewald has included themes like Gastroenterology and Oncology in his Internal medicine study. His Surgery study which covers Myeloid leukemia that intersects with Myelodysplastic syndromes, Haploinsufficiency and Lenalidomide.
His Pathology research includes themes of Fluorescence in situ hybridization and Trisomy 8, Cytogenetics. His Chronic lymphocytic leukemia research incorporates elements of Stromal cell, Bone marrow, Cohort and CD38. His Hematology study is concerned with the field of Immunology as a whole.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
Alan List;Gordon Dewald;John Bennett;Aristotle Giagounidis.
The New England Journal of Medicine (2006)
Establishment of an immature mast cell line from a patient with mast cell leukemia.
J. H. Butterfield;D. Weiler;G. Dewald;Gerald J. Gleich.
Leukemia Research (1988)
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Hugo F. Fernandez;Zhuoxin Sun;Xiaopan Yao;Mark R. Litzow.
The New England Journal of Medicine (2009)
Clinical and biologic implications of recurrent genomic aberrations in myeloma
Rafael Fonseca;Emily Blood;Montserrat Rue;David Harrington.
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
David P. Steensma;David P. Steensma;Gordon W. Dewald;Gordon W. Dewald;Terra L. Lasho;Terra L. Lasho;Heather L. Powell;Heather L. Powell.
The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis
Gordon W. Dewald;Robert A. Kyle;Gary A. Hicks;Philip R. Greipp.
Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997
Ian W. Flinn;Donna S. Neuberg;Michael R. Grever;Gordon W. Dewald.
Journal of Clinical Oncology (2007)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza;James A. Reeves;Eric J. Feldman;Gordon W. Dewald.
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
Anthony V. Moorman;Christine J. Harrison;Georgina A.N. Buck;Sue M. Richards.
Genomic abnormalities in monoclonal gammopathy of undetermined significance
Rafael Fonseca;Richard J. Bailey;Gregory J. Ahmann;S. Vincent Rajkumar.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: